Research Update
Research Update
From Hope Violette, Manager of Office Research
April 2010
Affiliation with DF/PCC for Clinical Trials
The Office of Research would like to announce that on 2/17/2010 Newton-Wellesley Hospital was approved as a Clinical Trial Affiliate of Dana-Farber/Partners Cancer Care. Newton-Wellesley Hospital was also recently approved as a Cancer and Leukemia Group B (CALGB) Affiliate. These affiliations will allow us to provide our oncology patients access to oncology studies that are sponsored by Dana-Farber/Partners Cancer Care and also to national studies sponsored by the National Cancer Institute.
This affiliation will be instrumental in meeting the mission of our Oncology Research Program which is to provide our adult patients and community members access to cutting-edge clinical trials in a state of the art cancer center. The goals of the research program are to advance the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases, increase the survival rates and improve the quality of life for all oncology patients.
From Bench to Bedside
Crestor™
The FDA recently announced that it is approving a new indication for the cholesterol lowering medication Crestor™ (rosuvastatin). Crestor™ will now be indicated for the primary prevention of cardiovascular disease to reduce the risk of stroke, heart attack, and the risk of arterial revascularization procedures (including coronary artery bypass graft, or bypass grafting of a peripheral artery or carotid artery, or angioplasty or stent placement) in individuals who have no clinically evident heart disease but are at an increased risk of heart disease due to the combined effect of defined risk factors. This announcement was based on the results of the multi-center clinical trial - Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin (JUPITER). Newton-Wellesley Hospital was one of the sites in this multi-center trial. Dr. Thomas Cunningham was the Principal Investigator at NWH.
More info on fda.gov
Xiaflex™
The FDA recently announced approval of Xiaflex™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord. This approval was based on the results of a study - A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects with Dupuytren's Contracture. Newton-Wellesley was one of 15 sites that were part of this clinical trial. Dr. Mark Belsky was the Principal Investigator at NWH and enrolled 16 subjects. Dr. Belsky is also participating in a long term follow-up study on these subjects.
Article
|
Your Community Hospital 
